- Home
- KMDA vs MCI Comparison
KMDA vs MCI Comparison
Compare KMDA & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- MCI
- Stock Information
- Founded
- KMDA 1990
- MCI 1971
- Country
- KMDA Israel
- MCI United States
- Employees
- KMDA N/A
- MCI N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- MCI Trusts Except Educational Religious and Charitable
- Sector
- KMDA Health Care
- MCI Finance
- Exchange
- KMDA Nasdaq
- MCI Nasdaq
- Market Cap
- KMDA 392.2M
- MCI 419.4M
- IPO Year
- KMDA N/A
- MCI N/A
- Fundamental
- Price
- KMDA $6.84
- MCI $20.13
- Analyst Decision
- KMDA Strong Buy
- MCI
- Analyst Count
- KMDA 2
- MCI 0
- Target Price
- KMDA $13.00
- MCI N/A
- AVG Volume (30 Days)
- KMDA 56.5K
- MCI 40.4K
- Earning Date
- KMDA 11-12-2025
- MCI 01-01-0001
- Dividend Yield
- KMDA 2.92%
- MCI 8.46%
- EPS Growth
- KMDA 27.97
- MCI N/A
- EPS
- KMDA 0.32
- MCI 1.82
- Revenue
- KMDA $169,517,000.00
- MCI N/A
- Revenue This Year
- KMDA $14.49
- MCI N/A
- Revenue Next Year
- KMDA $10.12
- MCI N/A
- P/E Ratio
- KMDA $20.74
- MCI $9.88
- Revenue Growth
- KMDA 9.67
- MCI N/A
- 52 Week Low
- KMDA $5.18
- MCI $12.96
- 52 Week High
- KMDA $9.16
- MCI $19.24
- Technical
- Relative Strength Index (RSI)
- KMDA 41.12
- MCI N/A
- Support Level
- KMDA $6.50
- MCI N/A
- Resistance Level
- KMDA $6.89
- MCI N/A
- Average True Range (ATR)
- KMDA 0.13
- MCI 0.00
- MACD
- KMDA -0.01
- MCI 0.00
- Stochastic Oscillator
- KMDA 38.50
- MCI 0.00
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About MCI Barings Corporate Investors
Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.